Amarin Q4 2022 net income $0.9M; revenue down 38% YoY; positive free cash flow $4M

AMARIN CORP PLCUK

2022-FY EPS reported -$0.26 revenue$369,193,000

Q4 2022 net product revenue $89.5M, down 38% YoY; U.S. revenue stabilized at $88.0M vs $87.9M in Q3.
GAAP net income $0.9M ($0.00 EPS); non-GAAP adjusted net income $7.3M ($0.02 EPS).
Positive free cash flow of $4M in Q4; cost savings program on track to exceed $100M target.
European expansion: VAZKEPA launched in 5 markets, pricing negotiations in 5 more; peak revenue potential $1B+ in Europe.
International: 6 regulatory approvals in 2022, plus New Zealand in Jan 2023; license agreement with CSL Seqirus for Australia/NZ.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AMARIN CORP PLCUK reported the three months ended December 31, 2022 results: revenue $90.2 million, net income $0.9 million, EPS $0.00 per share.

Period: the three months ended December 31, 2022
Revenue: $90.2 million
Net income: $0.9 million
EPS: $0.00 per share
Result: reported results

Exact text from the filing

Financial Update Total net revenue for the three months ended December 31, 2022 was $90.2 million, compared to $144.5 million in the corresponding period of 2021, a decrease of 38%. Net product revenue for the three months ended December 31, 2022 was $89.5 million, compared to $143.7 million in the corresponding period of 2021, a decrease of 38%. This decrease was driven primarily by a decrease in volume of VASCEPA sales to Amarin’s customers in the United States, which were adversely impacted by generic availability in the United States. USA net product revenue was $88.0 million for Q4 2022 compared to $87.9 million in Q3 2022. Amarin recognized licensing and royalty revenue of approximately $0.7 million and $0.8 million during the three months ended December 31, 2022 and 2021, respectively, from VASCEPA-related commercial sales from our partners in Canada, the China region and the Middle East. Cost of goods sold for the three months ended December 31, 2022 was $26.6 million, compared

View on SEC.gov

Browse all earnings releases →

AMARIN CORP PLCUK filing history →

Source: SEC EDGAR

accession 0000950170-23-005329

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.